Summary:
Researchers at 25 sites across the United States are recruiting 168
people with relapsing-remitting multiple sclerosis for a study
determining the safety and potential effectiveness of adding to disease-modifying therapy
the experimental, oral therapy that may promote the repair of
nerve-insulating myelin (PIPE-307). The study is sponsored by Contineum
Therapeutics.Details:Background:
PIPE-307 is a molecule that inhibits the muscarinic type 1 (M1)
receptor. The M1 receptor is a molecule in the brain that is known to
prevent the development of cells that make myelin, the insulation of
nerve fibers that is damaged in MS, and the formation of myelin itself.
This study will test whether adding PIPE-307 to approved
disease-modifying therapies is safe and potentially effective.Eligibility:
Participants should be 18 to 50 years old with a diagnosis of
relapsing-remitting MS. They should have been on any MS
disease-modifying therapy for six months.Participants
will be randomly assigned to receive one of two doses of PIPE-307 or
inactive placebo, once daily by mouth, for 26 weeks. Subjects may remain
on their existing disease modifying therapy. The primary outcomes being
measured are the number of people with adverse events and vision acuity
(an indication of the health of the optic nerve and vision pathways in
the brain). Secondary outcomes include measures of disability
progression and disease activity on MRI scans.The
study will include routine blood draws, neurological assessments, MRI
scans, and a remote sensor worn on the ankles to assess walking (for
those subjects who agree to wear the device for short intervals during
the study). People will undergo a series of screening assessments to
determine eligibility, and then return to the site for follow-up testing
at multiple times during the treatment period.Contact:
To learn more about the enrollment criteria for this study, and to find
out if you are eligible to participate, please contact the site nearest
you:
ARIZONAMegan HamiltonXenoscience, Inc.2601 N 3rd Street Suite 125Phoenix, AZ 85004602 274 9500SFLITMAN@XENOSCIENCE.COMMadison Turner, Ashely MitchellArizona Neuroscience Research, LLC3805 E Bell Rd. Suite 2400, Phoenix, AZ 85032480-210-8723madison@centerforneurologyandspine.com
ashely@centerforneurologyandspine.comCALIFORNIACasey Holden, RNREDI (Sutter Health)2850 Telegraph Avenue, Suite 110, Berkeley, CA 94705510-204-1610casey.holden@sutterhealth.orgCOLORADODevon GlazeColorado Springs Neurological Associates2312 N. Nevada Ave Suite 300Colorado Springs, CO 80907719-389-1126dglaze@csneuro.comFLORIDAKelly CalistriAqualane Clinical Research3200 Bailey Lane, Suite 180, Naples, FL 34105239-529-6780kelly@aqualaneresearch.comJodi MummertMS & Neuromuscular Center of Excellence3190 N McMullen Booth Road Suite 200, Clearwater, FL 33761(813) 431-4913jodi@gulfcoastcta.comClellia BergaminoVero Beach Neurology and Research Institute1040 37th Place Suite #201 Vero Beach FL 32960772-4492-7051 or 772-299-4304cbergamino@geodysseyrsch.comNicole DavisARS Brain and Spine1211 Dunlawton Ave. Port Orange, Fl. 32168386.204.0960 ext 632Nicole.davis@accelclinical.comGEORGIACarlyn R. Kappy, RD, LD, CCRPShepherd Center2020 Peachtree Road, NWAtlanta, GA 30309404-367-1375carlyn.kappy@shepherd.orgAndrea LevinVelocity Clinical Research6602 Waters Ave., Bldg C Savannah GA 31406912-790-4837alevin@velocityclinical.comINDIANASarah CollinsIndiana University School of Medicine Department of Neurology355 W. 16th Street, Suite 4700Indianapolis, IN 46202317-963-7315SQCollin@IU.eduKANSASLisa Schmidt, LPNUniversity of Kansas Medical Center3901 Rainbow Blvd, MS 2012, Kansas City, KS 66160913-588-3968lschmidt@kumc.eduMASSACHUSETTSJillian PellegriniNeurology Center of New England P.C.9 Payson Road, Suite 100, Foxboro, MA, 02035781-551-5812 opt 6jpellegrini@myneurodr.comMISSOURIAmber T. Smith, BS, MAWashington University School of MedicineDepartment of Neurology - John L. Trotter MS Center660 South Euclid Ave Campus Box 8111St. Louis MO, 63110314-362-3493 (p)ambertsmith@wustl.eduNEW MEXICOEmily Reese and Andrea RodriguezMS Specialty Clinic at the University of New Mexico's Health Sciences CenterNeurology Department MS Specialty Clinic
915 Camino de Salud NE, Albuquerque, NM 87131(505) 272-0959EjReese@salud.unm.eduandreRodriguez@salud.unm.eduNEW YORKAllison EmborskyDent Neurologic Institute3980 Sheridan Dr Amherst NY 14226716-558-3543
aemborsky@dentinstitute.comOKLAHOMAMicki DrakeOMRF Multiple Sclerosis Center of Excellence820 NE 15th St., Oklahoma City, OK 73104405.271.6242Micki-Drake@omrf.orgTENNESSEEKim PuccioSibyl Wray, MD Neurology, PC dba Hope Neurology2060 Lakeside Centre Way Knoxville, TN 37922865-299-5564kpuccio@hopeneuro.comTEXASZenaida HernandezBhupesh Dihenia MD PA3815 23rd Street, Lubbock, TX 79410 USA806-368-9415researchbhd@gmail.comElizabeth MartinezUniversity of Texas Health Science Center at Houston6410 Fannin, Ste 1014Houston, TX 77030(713) 704-4137elizabeth.martinez@uth.tmc.eduFahim DayaniClinical Trial Network713-484-6947fdayani@ctntexas.comWASHINGTONElisa McGeeUniversity of WashingtonMcMurray Building NWH campus, 1536 N 115th Street, Seattle, WA 98133206-598-9260emcgee@uw.eduAmelia JohnsonVirginia Mason Medical Center1100 9th Avenue Seattle, WA 98101(206) 287-6260amelia.johnson900@vmfh.orgTonya StiggerMultiCare Institute for Research & Innovation (MIRI)915 6th Ave. Suite #101, Tacoma, WA 98405253-403-1208Tonya.Stigger@multicare.orgDownload a brochure that discusses issues to think about when considering enrolling in an MS clinical trial (PDF)
Without participants in research studies, MS research would come to a standstill. Read more here.
Tuesday, May 28, 2024
MS Trial Alert: Investigators Recruiting People with Relapsing-Remitting Multiple Sclerosis for Study Adding a Potential Myelin Repair Therapy to Disease-Modifying Therapy
Sunday, February 4, 2024
Researchers Seeking Black Americans with MS to Participate in Genetics Studies
Help Find Clues to the Cause and Treatment of MS
Researchers at the University of California MS Genetics Project are
studying how MS affects Black Americans with MS. The university
maintains a unique repository of DNA and other biological materials with
the support of the National MS Society.
Why Does This Matter? New research shows that more
Black people are diagnosed with MS than previously thought and that they
may have a different disease course. Genes are known to play a role in
determining who is susceptible to developing MS and may also influence
the severity and course of the disease. Identifying the exact location
of MS genes could help determine who is at risk for developing the
disease and may provide clues to its cause, prevention, and better
treatment.
Focusing on Black, Hispanic/Latinx, Northern European, and other
ancestral groups, and searching for what is common and what is different
in their DNA sequences may help identify the precise genetic variants
that contribute to MS.
What is involved? It is not necessary to travel to San Francisco to participate in this study.
Once an individual has completed the initial online intake form and has
agreed to participate, they are emailed the links to two additional
online forms and sent a kit via express mail.
The kit includes a consent form, a health information privacy form, and a
medical records release form. The kit also includes everything
necessary for the blood draw, which can be taken to your local Quest
Diagnostics Lab, where the blood can be drawn and then returned in a
prepaid envelope to the UCSF MS Genetics Lab. There is no cost to the
study participants.
Individuals recently diagnosed with MS living in the San Francisco Bay
Area are also eligible to participate in an MRI study to identify
relationships between genetic profiles and tissue damage in the brain
and spinal cord.
Please note: this study cannot enroll international participants at this time.
Contact:
To participate or request additional information, please complete this brief intake survey.
OR you may contact the UCSF DNA directly:
Clinical Research Coordinator
UCSF Multiple Sclerosis Genetic Susceptibility Project
675 Nelson Rising Lane, Suite 235A, Box 3206
San Francisco, CA 94158
Email: msdb@ucsf.edu
Website: https://msgenetics.ucsf.edu/
Monday, December 25, 2023
Ways To Help Advance MS Research
Researchers are committed to finding solutions for everyone affected by
MS — the very people who hold the key to the answers. Without
participants in research studies, MS research would come to a
standstill.
People with MS, and sometimes family members, can help advance MS research by:
- responding to surveys online
- sharing their voices and ideas through NARCOMS and iConquerMSTM, organizations that amass volunteer-submitted information
- volunteering for clinical trials and other studies
- donating DNA from saliva and blood samples
- arranging for brain or spinal cord tissue donation to a tissue bank; this type of donation is incredibly valuable and truly appreciated by all who are involved in moving toward a world free of MS. Blood samples also can be donated for use in MS research studies.
Assess each opportunity and make an informed decision before agreeing to
participate — understand the possible benefits and risks. See our Guide to Participating in Clinical Trials.
Everyone can get involved to support research investment, or advocate so that Congress provides funding for MS research and supports other efforts such as understanding incidence and prevalence.
Participate in a Clinical Trial
Clinical trials help to determine if treatments and other interventions are safe and effective. Studies enrolling diverse populations are monitored to ensure that the rights and safety of all participants are protected. Without the participation of people with MS, it would be impossible to develop new and better solutions.
Surveys and Other Research Studies
Conducted by investigators seeking to answer scientific or health policy questions about MS, or by pharmaceutical or medical device companies aiming to develop or improve products for people with MS.
Participate in Genetic Studies
By donating DNA from blood samples, you are helping research that could lead to ending MS forever. Learn more about genetic studies and how you can participate.
Donate to Tissue Banks
People living with MS may hold the key to finding a cure. Learn more about tissue banks and donating brain and spinal cord tissue for researchers studying MS.
COVID-19 Studies Recruiting People with MS
Explore opportunities for participation in research studies seeking to understand the impacts of COVID-19 and how the vaccine can affect people living with MS.
Research Studies: Newly Diagnosed with MS
If you are new to MS, you have the chance to help advancements in MS research. Discover studies researching the earliest stages of MS looking for participants.
Register as a willing MS research participant to facilitate multicenter studies. Initiated by the Consortium of MS Centers.
Share information and ideas for research topics important to you. Each contribution and suggestion brings us closer to faster diagnoses and improved treatments.
Sunday, April 24, 2022
We Have Come So Far
When Sylvia Lawry started the MS movement in 1946 with the
founding of the National MS Society, research into multiple sclerosis
was almost non-existent. The disease took years to diagnose, and there
were no therapies proven to slow the course of MS.
Things have changed. Decades of research into MS and the basic workings
of the immune and nervous systems have built a critical platform of
knowledge now serving as a springboard for progress. The Society’s $1.06
billion research investment has fueled many of these advances, and
today’s picture looks different for many:
-
There are therapies specifically approved for treating and managing MS, and more potential MS therapies in development today than at any other time in history.
-
MS is more quickly diagnosed, enabling early and sustained therapy to slow disease activity
-
There is much greater awareness of the many symptoms of MS and ways to address them to improve quality of life
-
Scientists are making breakthroughs in identifying risk factors that can increase a person’s susceptibility to MS, which will help lead to ways to prevent the disease.
We have made progress but more must be done for those living with forms of progressive MS for which there are limited treatment options. The hope – and potential - for new, more effective treatments for MS has never been greater. We are part of a global movement of millions of people working toward a world free of MS.
Critical Milestones
1981 - First MRI pictures of a brain affected by MS are produced, revolutionizing MS diagnosis
1984 - First modern documentation of cognitive problems in MS
1988 - First demonstration, using MRI, of significant lesion activity in MS, even when the disease seems quiet
1993 - First disease-modifying therapy for relapsing MS approved
1996 - First proof that aerobic exercise improves physical and psychological well-being in MS
1999 - Society grantees first to isolate immature cells in the adult
brain capable of developing into replacements for myelin-making cells
destroyed by MS
2003 - Italian researchers transplant cells to enhance nerve tissue repair in mice with MS
2004 - Pivotal study by Society Fellow shows that African-Americans tend to have a more aggressive course of MS than Caucasians
2005, 2010, 2018 - “McDonald Criteria” for diagnosing MS updated by Society Task Force, speeding time to diagnosis for many
2007 - With support from Society to International MS Genetics
Consortium, two genes are confirmed to be linked to MS risk; many more
uncovered since
2007 - First large-scale trial of sex hormone estriol gets underway in
women with MS, a result of the Society’s targeting of gender differences
2010 - First oral disease-modifying therapy approved for relapsing MS
2012 - Launch of Progressive MS Alliance to speed the development of therapies
2013 - Studies hint that exercise and rehabilitation can improve many functions and even help rewire the brain
2014 - First large, phase 2 clinical trials of myelin repair strategy for MS are launched
2015 - A phase 2 clinical trial co-funded by the Society suggests a pill
used to treat epilepsy (phenytoin) has the potential to slow the
accumulation of disability in people with MS
2015 - Results of phase 2 trial of anti-LINGO suggests it has potential as myelin repair strategy
2015 - Society co-hosts international conference on cell-based therapies to forge next steps for cell therapy in MS
2015 - Society funding helps launch MS Microbiome Consortium to promote
research on role of gut bacteria in MS progression and treatment
2015-16 - Two large-scale clinical trials break through long-standing
barrier by showing benefit in primary progressive and secondary
progressive MS
2016 - Positive results announces from two studies of bone
marrow-derived stem cells (HSCT) in people with aggressive, relapsing
MS; more research focuses on who might benefit and how to reduce risks
2016 - Society-funded International Consortium of MS Genetics identifies
200 genetic variations linked to MS, offering new leads to how genes
and other factors that make people susceptible to developing MS
2016 - Society launches two new studies testing the ability of dietary
approaches to treat MS symptoms and improve quality of life
2016-17 - International Progressive MS Alliance awards three large-scale
Collaborative Network Awards to promote solutions for people with
progressive MS
2017 - FDA approves Ocrevus (ocrelizumab) as first disease-modifying
therapy for primary progressive MS, and also as a therapy for relapsing
MS
2017 - International team co-sponsored by the Society revised MS
diagnostic criteria to speed diagnostic process and reduce incidence of
misdiagnosis
2018 - FDA approves expansion of the use of Gilenya to include children
and adolescents 10 years of age or older with relapsing MS, the first
therapy specifically approved to treat pediatric MS
2018 - A Phase 2 trial showed that ibudilast could reduce brain atrophy
in progressive MS. The trial was funded collaboratively by the National
MS Society, the NINDS, its NeuroNext trials network, with support by
MediciNova, the supplier of ibudilast
2018-19 - Results announced from several studies of bone marrow-derived
stem cells in people with aggressive, relapsing MS. More research is
focused on who might benefit and how to reduce risks
2019 - Study sponsored by the National MS Society conducted by leading
experts estimates that nearly 1 million adults are living with MS in the
United States. This is more than twice the previously reported number
2019 - FDA approves oral Mavenclad (cladribine) for adults with
relapsing forms of MS, and also approves oral Mayzent (siponimod) for
adults with clinically isolated syndrome (an initial neurological
episode) and relapsing forms of MS
2019 - FDA approved Vumerity™ (diroximel fumarate, Biogen and Alkermes plc) for relapsing MS
2020 - National MS Society releases recommendations for aHSCT-bone marrow transplant for MS
2020 - FDA approves generic form of Tecfidera for relapsing MS
2020 - FDA approves Kesimpta® (ofatumumab) for relapsing MS
2020 - Society-supported Wellness Research Group publishes exercise and physical activity recommendations for ALL people with MS
2020 - National MS Society, Consortium of MS Centers, and others establish the North American MS COVID-19 Clinical Database
2020 - FDA approves Oral Bafiertam™ (Monomethyl Fumarate) for relapsing MS
2020 - FDA approves Oral Zeposia® (Ozanimod) for relapsing MS
Download a Timeline of MS Research Progress (.pdf).
Wednesday, March 9, 2022
Novel Twins Study Pinpoints Immune System Activity Early in MS Not Accounted for by Genes
In this study, researchers used state-of-the-art technologies such as mass cytometry (exploring millions of cells) and machine learning (an automated type of data analysis) to look at the immune profiles of these sets of twins. The results showed key differences in docking sites on immune messenger proteins (cytokines), that affect how immune cells communicate with each other. These differences left people with MS susceptible to greater activation of the cells that drive immune attacks in MS.
Although twins do share early environmental experiences (such as prenatal influences), these results suggest that a later environmental factor or factors might be at play. Ongoing research by scientists around the world are working on identifying those factors and how they launch the disease.
Read more from the University of Zurich
Read the paper, available from Nature via Open Access
Wednesday, June 6, 2018
New MS Research
Research on immune activity in MS
- Understanding components of the immune system such as T cells, B cells, and antibodies
- Identifying new targets for therapeutic intervention while leaving the rest of the immune system capable of fighting infections
- Identifying substances and processes involved in the injury of axons
- Identifying the body’s natural immune messenger molecules that can either turn on or turn off immune attacks
We’re making progress
Researchers co-funded by the National MS Society report study results indicating that “Tregs” – regulatory immune cells that are known to be dysfunctional in people with MS – play a role in promoting formation of new myelin following damage. If the results are confirmed through further research, these basic laboratory studies could eventually be translated to promising new therapeutic approaches to stimulating myelin repair to restore function in people with MS. Read more
Treatment with ATX-MS-1467 (Apitope) – an injected immune therapy whose early development was supported by the National MS Society through Fast Forward, the Society’s commercial research funding program – was reported to reduce disease activity on MRI scans in two small open-label studies involving people with relapsing MS. This is an approach to identify pieces of human proteins, called “peptides,” that might be able to reinstate “immune tolerance” – in effect, train immune cells to ignore myelin – to suppress MS attacks. Read more
Scientists at the University of Florida, funded in part by the National MS Society, took a novel approach to turn off immune attacks in mice with an MS-like disease. The team used a harmless virus to deliver a gene coding for a specific component of myelin, a key target of immune attacks in MS. Further research is needed to verify and refine this approach before it can be tested in people. Read more
Sunday, September 17, 2017
Study Strengthens Link Between Low Vitamin D Levels and Risk of MS
- A study based on stored blood samples of 800,000 pregnant Finnish women found that vitamin D levels might predict who is at risk for later developing MS.
- Vitamin D blood levels of 1,092 women later diagnosed with MS were compared to those of 2,123 women around the same age and region who did not develop the disease.
- Women who developed MS later had average D levels lower than the women who didn’t.
- More research is needed on how to best supplement vitamin D and to know whether and who it might help. Read more more about Vitamin D and MS.
- The study was published on September 13, 2017 in Neurology.
DETAILS
Background: Researchers believe that several genetic and environmental factors influence whether a person will get MS. These factors may also impact the severity of the disease. Scientists are eager to find risk factors for MS that can be modified to possibly prevent MS and reduce disease activity. Research is increasingly pointing to reduced levels of vitamin D in the blood as a risk factor for developing MS, and studies are underway to determine if vitamin D levels influence MS disease activity.
This Study: This study -- the largest such study to date – took advantage of a unique resource: stored blood samples from 800,000 Finnish women who had undergone routine prenatal testing during pregnancy. The study was designed to determine whether and to what extent vitamin D deficiency is associated with future risk of developing MS. The team identified 1,092 of the women who were later diagnosed with MS. The researchers compared their vitamin D levels to those of 2,123 women who were about the same age and lived in the same area but did not develop MS. Of those women whose medical records were available for examination, an average of 9.5 years had lapsed between the time of the first blood sample and the date of an MS diagnosis. For this study, classifications of blood levels of vitamin D (25-hydroxyvitamin D) included “deficient” (less than 30 nmol/L) and “adequate” (greater than or equal to 50 nmol/L).
Results: The team found that overall as vitamin D levels increased, the risk of later developing MS decreased. Women with the greatest deficiency in vitamin D had a twofold increase in the risk of developing MS, and those with the highest vitamin D levels had the lowest risk of a later MS diagnosis. Most of the women in the study were considered to have deficient or insufficient levels of vitamin D. Of the women who developed MS, 58 percent had deficient levels of vitamin D, compared to 52 percent of the women who did not develop the disease.
The researchers conclude that the results directly support vitamin D deficiency as a risk factor for MS and that correcting this among reproductive age women may reduce their future risk of developing MS. In addition, a previous study of this same group of women found that maternal vitamin D deficiency during pregnancy doubled the risk of MS in their offspring, and a Danish study found that low vitamin D levels in infants was associated with an increased MS risk in adulthood, suggesting that improving a woman’s vitamin D levels during pregnancy may also reduce the risk of MS in her children.
The study, by a team including Drs. Kassandra Munger and Alberto Ascherio (Harvard T. H. Chan School of Public Health in Boston), was published on September 13, 2017 in Neurology.
Comment: This largest study of its kind to date adds to growing evidence that low levels of vitamin D increase the likelihood of developing MS. Since this study included only women, who were mostly white, the results may not apply to men or to other racial groups. It also did not account for other potential risk factors that may have played a role.
An editorial in the same issue of Neurology by Drs. Ruth Ann Marrie Christopher Beck addresses the question of whether there is enough evidence now to make sweeping recommendations on vitamin D supplementation. They note, “Vitamin D supplementation is a simple intervention that would be highly cost-effective even if it prevents only a proportion of MS cases...,” concluding, “It is time to take an active approach to preventing MS, at a minimum targeting those individuals with an elevated risk of MS, including smokers, the obese, and those with a family history of MS.” Read more more about Vitamin D and MS
Friday, July 28, 2017
Researchers Recruiting People with Primary Progressive MS for Genetics Studies – Key to finding treatment options
Rationale: Specific subtle variations in the human genome are known to play a role in determining who is susceptible to developing multiple sclerosis, and may also influence the course of the disease. People living with MS can make a difference in studies searching for these genes by donating their DNA with a blood sample. Identifying the exact location and role of MS genes could help determine who is at risk for developing the disease and can provide clues to its cause, prevention, and lead to better treatments.
Details: Once an individual has completed the initial online intake form, they will receive a call from the study coordinator to discuss details and answer any questions. The consent form and health information privacy form can be signed electronically. Participants will then be emailed a link to two additional short online surveys and sent a blood-collection kit. The kit includes everything necessary for the blood draw, which can be taken to your local Quest Diagnostics Lab and returned in a prepaid envelope to the lab at UCSF. There is no cost to participants.
Contact: To participate or request additional information, please complete a brief intake survey.
OR you may contact UCSF directly:
Clinical Research Coordinator
UCSF Multiple Sclerosis Genetic Susceptibility Project
675 Nelson Rising Lane, Suite 235A, Box 3206
San Francisco, CA 94158
Email: msdb@ucsf.edu
Toll Free Phone: 1-866-MS-Genes (1-866-674-3637) or Office Phone: (415) 502-7202